Eric Dane explains why he feels 'lucky' amid ALS battle: See video
"Euphoria" actor Eric Dane said he is grateful and privileged to have financial stability amid his ongoing battle with ALS, but warned that many other American families are not.
The "Grey's Anatomy" alum spoke at U.S. Health Secretary Robert F. Kennedy Jr.'s hearing to discuss the Monday, June 23 announcement that several health insurance companies plan to simplify and reduce prior authorizations over the next year and a half.
UnitedHealthcare, Blue Cross Blue Shield and Kaiser Permanente were among the companies that aim to streamline the common process of vetting requests before allowing doctors to bill for medical services or prescriptions.
In April, the 52-year-old San Francisco native revealed he was diagnosed with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. At Monday's press conference, Dane applauded the insurance industry for coming together to offer other ALS patients "more certainty, faster answers and more hopes for recovery."
"Some of you may know from TV shows such as 'Grey's Anatomy' which I play a doctor, but I am here to today to speak briefly as a patient," he said. "When that diagnosis hits and you find out that you're sick, your life becomes filled with great uncertainty. And the worst thing we could do is add even more uncertainty for patients and their loved ones with unnecessary prior authorization."
Prior authorization has criticized by many doctors and patients who argue the practice routinely delays or denies care, according to various surveys and government oversight reports. The newly unveiled changes could impact 257 million Americans who are covered by private commercial insurance, Medicare Advantage and Medicaid managed care plans.
"Anything we can do to give patients more certainty with fewer delays is a worthwhile endeavor," he said. "I've been fortunate and have the means to access great care. I am lucky. Not everyone is in the same position."
Eric Dane says right arm has 'completely stopped working'
Last week, Dane shared that his ALS has progressed to the point that his right arm has stopped functioning.
"I have one functioning arm," he told Diane Sawyer on a June 16 "Good Morning America" interview. "My left side is functioning. My right side has completely stopped working."
The actor said he expects just a few more months before "I won't have my left hand either," which he called "sobering." And while he luckily has not had any issues walking, he added that he's also "worried" about his legs.
Dane is arguably best known for playing played the plastic surgeon Dr. Mark Sloan, nicknamed "McSteamy" on ABC's "Grey's Anatomy" from 2006 to 2012. He is also expected to reprise his role as Nate Jacob's father Cal Jacobs in the upcoming third season of HBO's "Euphoria."
Contributing: Ken Alltucker and Brendan Morrow, USA TODAY
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Hims & Hers stock plunges after Novo Nordisk ends its brief partnership
Hims & Hers stock plunged 35% on Monday after its collaboration with Novo Nordisk came to a halt. The Danish pharmaceutical giant said it was ending the partnership because Hims is selling and promoting a cheaper copycat of Novo's blockbuster weight loss drug, Wegovy. "Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," Novo said in a statement on Monday. Novo added that according to its investigation, telehealth companies that compound semaglutide drugs use ingredients "manufactured by foreign suppliers in China." Novo said that Hims would no longer have direct access to Wegovy. Novo's stock closed more than 5% lower on Monday. In a statement on X on Monday, Hims' CEO Andrew Dudum said Novo was being anti-competitive and that Hims will continue to provide a range of treatments, including Wegovy. "In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients," he wrote. "We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice." Hims' stock has been on a roller coaster this year, with shares dropping and jumping sharply on new developments in the weight loss drug industry. At the end of April, Hims stock surged 20% after Novo announced a long-term collaboration with Hims to make obesity treatments accessible on the Hims platform. The announcement came just months after Hims' CEO said that the company would no longer sell compounded versions of Novo's weight loss drugs. Instead, it would sell "personalized" dosages of Wegovy under rules allowing it for clinical reasons such as decreased side effects. The company's stock fell over 19% following Dudum's remarks on Novo. The company was allowed to make legal copies of Novo's weight loss and diabetes drugs Ozempic and Wegovy during a shortage that began in 2022. In February, the US Food and Drug Administration removed semaglutide injection products from its shortage list and gave compounders 60-90 days to stop making copies. Hims is up 74% this year. Novo is down 19% this year on worries that the company is rapidly losing market share to American pharmaceutical rival Eli Lilly.
Axios
4 hours ago
- Axios
Why al dente pasta is better for your health
Many Americans cook their pasta for too long, when nutritionists and chefs say al dente is best. Why it matters: How pasta is prepared could mean the difference between a health-optimized dinner and one that spikes your blood sugar. How it works: When pasta is cooked al dente, it has a lower glycemic index (a measure of how quickly specific foods raise blood sugar) than overcooked noodles. A higher GI can potentially leave diners hungry and tired after eating. Firmer pasta also requires more chewing, helping with digestion. It's a small difference that can be especially important for anyone tracking their blood sugar or looking to punch up their meal's nutrition. What we're hearing: Minutes matter. Al dente means "to the tooth" in Italian. "You want to feel something in your teeth. Nothing like Wonder Bread or marshmallows," Mediterranean diet ambassador and chef Amy Riolo told Axios. If it's crunchy, though, it's not ready. Denver-based chef Elise Wiggins recommends cooking pasta until it's three-quarters done (still "stiff-looking"), then finishing it in the sauce. Mushy pasta's glycemic index could mimic that of white rice, while al dente pasta is closer to farro or barley, says Melissa Mroz-Planells, Seattle-based spokesperson for the Academy of Nutrition and Dietetics. Boxed spaghetti typically cooks in just 9 minutes, and Riolo told Axios it's best to check for doneness at 7 minutes. The boiling process is also important: Water should be rapidly boiling (with big bubbles at the top). Add salt (at least a teaspoon). Salt also speeds up the boiling process. Add pasta and stir. Turn the heat down to medium-high or medium. (You don't want the water boiling over.) Fun fact: Barilla created Spotify playlists that match its pasta cook times. Never rinse pasta after cooking because that washes away nutritional value, Mroz-Planells says. Plus, that surface starch is "essential for the sauce to adhere well," says Claudia Bouvier, co-founder of Boulder-based heirloom wheat pasta company Pastificio. Also, don't add oil to the water, award-winning chef and TV personality Tiffany Derry warns. "That's just a waste, and it keeps your sauce from sticking like it should." Oil can be used after the pasta is cooked.
Yahoo
5 hours ago
- Yahoo
Kennedy says health insurers promise to change prior authorization process
WASHINGTON — Health and Human Services Secretary Robert F. Kennedy Jr. said Monday that the country's largest health insurers have promised to take steps to streamline the often-criticized prior authorization process, which can delay or deny patients' access to care. Prior authorization is a cost-cutting tool used by health insurers that requires them to sign off on tests, procedures or drugs before patients can get them. The insurance tactic drew renewed attention last year after the fatal shooting of Brian Thompson, the CEO of UnitedHealth's insurance arm, in New York City. Patients and doctors say prior authorization creates too many roadblocks, forcing people to wait days or weeks for needed treatments or denying them altogether. About 1 in 6 insured adults say they've had prior authorization problems, according to a survey from KFF, a health policy research group. Kennedy said a number of large insurance companies — including Blue Cross Blue Shield Association, Cigna, Elevance Health, GuideWell, Humana, Kaiser Permanente and UnitedHealthcare — pledged to make the changes, which will be implemented across private insurance, Medicare Advantage and Medicaid. AHIP, a health insurance industry trade group, said the changes could benefit 257 million people in the United States. Experts stressed, however, that prior authorization isn't going away. It's 'going to streamline it in some incremental ways only,' said Dr. Adam Gaffney, a critical care physician and assistant professor at Harvard Medical School. Health insurance companies have made similar commitments to fix prior authorization in the past, a fact Kennedy and Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services (CMS), acknowledged at a media event Monday. In 2018 and again in 2023, health insurance companies made commitments to reform prior authorization, Oz said, but many failed to implement such reforms. Asked what's different this time, he said, 'There's violence in the streets over these issues,' alluding to the shooting of Thompson. AHIP — formerly America's Health Insurance Plans — detailed the steps health insurance companies committed to in a news release earlier Monday. Starting next year, if patients switch insurance plans while they are receiving treatment, their new plans will honor the existing prior authorizations for similar care for up to 90 days. In addition, next year, insurers will need to provide easier-to-understand explanations when they deny authorizations and offer guidance about how to appeal. Insurers have pledged to have medical professionals review all authorization denials, though AHIP said that is something that insurers say they already do. Insurers have also committed to streamline the prior authorization process by making it easier to submit requests online by 2027. At least 80% of electronic requests will be answered in real time by 2027, AHIP said. Plans may also reduce the number of medical services subject to prior authorizations in certain cities or states — though specific commitments about what that might include were lacking. Chris Klomp, who leads the Medicare program at CMS, said the agency would like insurers to roll back prior authorization requirements for common services, including colonoscopies, cataract surgery and childbirth. Kennedy also said CMS is working with insurers to make it easier to get prior authorization for diagnostic imaging, physical therapy and outpatient surgery. Gaffney criticized the pledges, saying insurers have had decades to change their practices. 'Talk is cheap,' Gaffney said. 'More fundamental reform will be needed to address the ubiquitous barriers to care imposed by insurance firms.' Kaye Pestaina, director of the program on patient and consumer protection at KFF, said some of commitments could have direct impacts on patients, such as honoring existing prior authorizations for three months after patients switch insurers. This article was originally published on
